论文部分内容阅读
目的探讨扶正抗癌方联合FOLFOX方案(奥沙利铂+亚叶酸钙+5-氟尿嘧啶)治疗中晚期结肠癌的疗效。方法 120例中晚期结肠癌患者根据治疗方案分为对照组(57例)与观察组(63例),对照组患者采用FOLFOX方案治疗,观察组患者采用扶正抗癌方联合FOLFOX方案治疗。结果①治疗前,两组患者癌胚抗原(CEA)、KPS评分相比差异无统计学意义(P>0.05)。治疗后,观察组患者CEA显著低于对照组,差异有统计学意义(P<0.05),KPS评分显著高于对照组,差异有统计学意义(P<0.05)。②观察组患者治疗效果显著优于对照组,差异有统计学意义(P<0.05)。③两组患者血小板抑制、肝肾功能损害、口腔黏膜炎、神经毒性等并发症发生率相比差异无统计学意义(P>0.05),观察组患者白细胞减少、消化道反应、红细胞抑制等并发症发生率显著低于对照组,差异有统计学意义(P<0.05)。结论扶正抗癌方联合FOLFOX方案治疗中晚期结肠癌的疗效确切,值得临床推广应用。
Objective To investigate the curative effect of Fuzheng anti-cancer combined with FOLFOX regimen (oxaliplatin + leucovorin + 5-fluorouracil) in the treatment of advanced colon cancer. Methods 120 patients with advanced colon cancer were divided into control group (57 cases) and observation group (63 cases) according to treatment regimen. Patients in control group were treated with FOLFOX regimen and observation group were treated with Fuzheng anticancer treatment combined with FOLFOX regimen. Results ① There was no significant difference in CEA and KPS between the two groups before treatment (P> 0.05). After treatment, the CEA in the observation group was significantly lower than that in the control group (P <0.05). The KPS score was significantly higher than that in the control group (P <0.05). ② The treatment group in the observation group was significantly better than the control group, the difference was statistically significant (P <0.05). ③ There was no significant difference in the incidence of complications such as platelet inhibition, hepatic and renal dysfunction, oral mucositis and neurotoxicity between the two groups (P> 0.05). The incidence of leukopenia, digestive tract reaction and erythrocyte inhibition The incidence of disease was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion Fuzheng anticancer treatment combined with FOLFOX regimen in the treatment of advanced colon cancer is effective and worthy of clinical application.